



CIN NO.: L24230WB1982PLC034492

Date: 29th January, 2025

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001
Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 29th January, 2025
Scrip Code: 12130 (CSE)

This is to inform you that, Pursuant to 33 and 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Director at its meeting was held its Registered Office on Wednesday, 29th January, 2025 (**commenced at 02:00 P.M. and concluded at 02:45 P.M.**) have inter-alia considered, approved and adopted the following agenda:

1. The Standalone Unaudited Financial Results of the Company for the 03rd quarter ended 31st December, 2024 along with Limited Review Report by the Statutory Auditors.
2. The undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

This information is also available on Company's website: www.adinathbio.com and on the Stock exchange website: www.cse-india.com.

The Company would be publishing Extract of Un-Audited Financial Result for the 03rd quarter ended 31st December, 2024, in accordance with Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015.

Request to you kindly take the above on record.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited

SUNIL Digitally signed
by SUNIL KUMAR
Date: 2025.01.29
14:48:26 +05'30'
KUMAR

Sunil Kumar
Managing Director & CEO
DIN: 07777351



| Statement of Standalone Unaudited Financial Results for the 3rd quarter and nine months ended 31st December, 2024 | | | | | | | |
|---|---|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------|
| Sl. No. | Particulars | PART I | | | | | (Rs. In Lakhs) |
| | | Quarter Ended | | | Nine Months Ended | | Year Ended |
| | | Unaudited 31-12-2024 | Unaudited 30-09-2024 | Unaudited 31-12-2023 | Unaudited 31-12-2024 | Unaudited 31-12-2023 | Audited 31-03-2024 |
| 1 | Income from operations | | | | | | |
| | (a) Net Sales / income from operations | - | - | - | - | - | - |
| | (b) Other Income | 1.785 | 2.105 | 2.105 | 6.577 | 7.035 | 9.150 |
| | Total income from operations (net) | 1.785 | 2.105 | 2.105 | 6.577 | 7.035 | 9.150 |
| 2 | Expenses | | | | | | |
| | (a) Changes in inventories of finished goods, work-in-progress and stock-in-trade | - | - | - | - | - | - |
| | (b) Employee benefits expense | 1.363 | 1.361 | 1.357 | 4.084 | 4.068 | 5.427 |
| | (c) Finance Cost | - | - | - | - | - | - |
| | (d) Depreciation and amortisation expense | - | - | - | - | - | - |
| | (e) Other expenses | 0.769 | 1.339 | 1.209 | 5.170 | 5.365 | 6.852 |
| | Total expenses | 2.132 | 2.700 | 2.566 | 9.254 | 9.433 | 12.279 |
| 3 | Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2) | (0.347) | (0.595) | (0.461) | (2.677) | (2.398) | (3.129) |
| 4 | Exceptional & Extraordinary Items | - | - | - | - | - | - |
| 5 | Profit / (Loss) before Tax (3 ± 4) | (0.347) | (0.595) | (0.461) | (2.677) | (2.398) | (3.129) |
| 6 | Tax expense | | | | | | |
| | Current Tax | - | - | - | - | - | - |
| | Deferred Tax | - | - | - | - | - | - |
| | Earlier Years | - | - | - | - | - | - |
| | Total Tax Expenses | - | - | - | - | - | - |
| 7 | Net Profit/(Loss) after tax(5 ± 6) | (0.347) | (0.595) | (0.461) | (2.677) | (2.398) | (3.129) |
| 8 | Other Comprehensive Income / (Loss) | - | - | - | - | - | - |
| 9 | Total Comprehensive Income / (Loss) (7 ± 8) | (0.347) | (0.595) | (0.461) | (2.677) | (2.398) | (3.129) |
| 10 | Paid-up equity share capital | 2,207.426 | 2,207.426 | 2,207.426 | 2,207.426 | 2,207.426 | 2,207.426 |
| | (Face Value in Re.) | 1 | 1 | 1 | 1 | 1 | 1 |
| 11 | Reserves excluding Revaluation Reserves | - | - | - | - | - | (2,213.741) |
| 12 | Earnings Per Share (not annualised except for year ended): | | | | | | |
| | Basic & Diluted | (0.000) | (0.000) | (0.000) | (0.001) | (0.001) | (0.001) |

Notes:

- The above Unaudited Financial Results have been reviewed by the Audit Committee and adopted by the Board of Directors at their meeting held on 29th January, 2025.
- The results are based on the financial statements prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter ended and nine months ended December 31, 2024 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and issued an unqualified report in this behalf.
- Provisions for current year income tax and deferred tax will be made at the end of the year except for the earlier year which are accounted on the basis of assessment orders received by the company.
- Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

By order of the Board
For Adinath Bio-Labs Limited

SUNIL
KUMAR

Digitally signed by
SUNIL KUMAR
Date: 2025.01.29
14:48:46 +05'30'

Sunil Kumar
MD and CEO

DIN No.:07777351



Date: 29th January, 2025.

Place: Kolkata

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Adinath Bio-Labs Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the quarter and nine months ended on 31st December, 2024 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA& Co.
Chartered Accountants
Firm registration No: 003822C


Kamal Piyush
Partner

Membership No: 083399
UDIN: 25083399BM0VUX8260

Place : New Delhi
Date : January 29, 2024



CIN NO.: L24230WB1982PLC034492

Date: 29th January, 2025

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Non- applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc..-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Sunil Kumar, Managing Director & Chief Executive Officer of Adinath Biolabs Limited hereby certify that Compliances of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company, as the company has not issued any share by way of public issue, right issue, preferential issue etc. during the 03rd quarter ended 31st December, 2024.

You are requested to take the above information in your records.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited

SUNIL
Digitally signed
by SUNIL KUMAR
Date: 2025.01.29
14:49:08 +05'30'

Sunil Kumar
Managing Director & CEO
DIN: 07777351

